bioMérieux : Back on an important level
| Entry price | Target | Stop-loss | Potential |
|---|
|
€95.2 |
€102 |
€92 |
+7.14% |
|---|
bioMérieux shares are closing back in on major support levels around 94.3 EUR based on daily price data, which could offer attractive entry points.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company has a good ESG score relative to its sector, according to Refinitiv.
● The company is in a robust financial situation considering its net cash and margin position.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● With a 2024 P/E ratio at 24.47 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
● The valuation of the company is particularly high given the cash flows generated by its activity.
● The company is not the most generous with respect to shareholders' compensation.
● For the last few months, analysts have been revising downwards their earnings forecast.
● The average consensus view of analysts covering the stock has deteriorated over the past four months.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on BIOMÉRIEUX since 2023-07-27
.
BIOMÉRIEUX 
